Quell Therapeutics to Present at Upcoming Investor Conferences in 2022

LONDON and BOSTON, Nov. 22, 2022 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), a leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will participate in two upcoming investor conferences:

• Piper Sandler 34th Annual Healthcare Conference
  Format: Company Presentation
  Date: Tuesday, November 29, 2022
  Time: 1:10 p.m. ET
  Location: New York, New York
  
  
• 5th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside Chat
  Date: Thursday, December 1, 2022
  Time: 9:15 a.m. ET
  Location: Virtual

About Quell Therapeutics

Quell Therapeutics is a world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.

The Company is leveraging its pioneering phenotype lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches.

Quell's lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases. www.quell-tx.com.

Contacts

Luke Henry, Chief Business Officer
Quell Therapeutics
[email protected]

Media: Mark Swallow, Frazer Hall, Eleanor Perkin
MEDiSTRAVA Consulting
+44 (0) 203 928 6900
[email protected]

Investors: Christina Tartaglia
Stern Investor Relations, Inc.
+1 212 362 1200
[email protected]

SOURCE Quell Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED